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Aim: To examine whether sodium-glucose co-transporter-2 (SGLT2) inhibitors are associated with
a higher risk of lower-extremity amputation than dipeptidyl-peptidase-4 (DPP-4) inhibitors and
sulphonylureas.
Methods: We conducted a retrospective cohort study, using the MarketScan Commercial Claims
and Encounters Database (2013-2015), to compare the incidence of lower-extremity amputation
(LEA) between initiators of SGLT2 inhibitors and initiators of two second-line drugs, DPP-4 inhibi-
tors and sulphonylureas (SUs). We estimated crude incidence rates (IRs) and adjusted hazard ratios
(aHR), with 95% confidence intervals (CIs), before and after propensity-score weighting. We addi-
tionally conducted sensitivity analyses using a comparator group of all non-metformin, non-SGLT2
inhibitor glucose-lowering drugs, as previous studies used this approach.
Results: In a cohort of 328 150 individuals aged 18 to 64 years, the IR of LEA ranged from 1.5
to 2.4 per 1000 person-years. In as-treated analysis, the estimated hazard of LEA was increased
among SGLT2 inhibitor initiators compared to DPP-4 inhibitor initiators (aHR 1.69, 95% CI
1.20-2.38), but not compared to SU initiators (aHR 1.02, 95% CI 0.67-1.55) or non-metformin,
non-SGLT2 inhibitor initiators (aHR 1.02, 95% CI 0.54-1.93). Results were consistent in
intention-to-treat analysis and across a number of sensitivity analyses.
Conclusions: Among commercially insured patients in the United States, our results suggest that
initiation of SGLT2 inhibitors may increase the risk of LEA compared to initiation of DPP-4
inhibitors. Contrasting results when comparing SGLT2 inhibitor initiators to DPP-4 inhibitor and
SU initiators highlight the importance of choosing appropriate comparator drugs when addres-
sing comparative effectiveness and safety questions that can inform clinical decision-making.
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1 | INTRODUCTION
Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce blood glu-
cose in type 2 diabetes mellitus (T2DM) by inhibiting renal glucose
reabsorption in the proximal tubule, thereby increasing urinary glu-
cose excretion.1,2 In addition to glycaemic efficacy,1,3 observational
and cardiovascular outcome studies demonstrate that SGLT2 inhibi-
tors have cardio-renal protective effects versus placebo and other
glucose-lowering drugs (GLDs).4–7
Safety concerns, however, were raised by the Canagliflozin Car-
diovascular Assessment Study (CANVAS) programme, which revealed
a significant increase in the risk of overall amputation (hazard ratio
[HR] 1.97, 95% confidence interval [CI] 1.41-2.75), primarily of the
toe or forefoot, among patients randomized to canagliflozin, with
median follow-up of 126 weeks.5 This represents an important finding
given that T2DM is the leading cause of non-traumatic lower-
extremity amputations (LEAs).8 In response, the US Food and Drug
Administration issued a bulletin regarding amputation risk in May
20169 and a drug-labelling change in July 2017.10 Recently, several
observational studies have sought to corroborate this finding in
broader populations, with mixed conclusions.11–16
To address the variation in observed risk of amputation with
SGLT2 inhibitors, we implemented an active comparator new-user
(ACNU) study17 to estimate and compare the risk of LEA between
patients initiating SGLT2 inhibitors and patients initiating two second-
line GLDs, dipeptidyl peptidase-4 (DPP-4) inhibitors and sulphonylur-
eas (SUs), which are prescribed as alternatives to SGLT2 inhibitors.
Specifically, we explored how selection of different analytical popula-
tions and comparators impacted the risk estimates of LEA with SGLT2
inhibitors, and how such choices may have contributed to differences
in published findings in this domain.
2 | METHODS
2.1 | Data source
We conducted a cohort study using the Truven Analytics' IBM® Wat-
son Health MarketScan® Commercial Claims and Encounters (CCAE)
Database from 2013 to 2015. MarketScan data contain inpatient, out-
patient, and pharmaceutical claims and encounters data linked with
demographic and enrolment information from ~350 insurance payers
in the United States.18 This database is representative of the US pop-
ulation with employer-based insurance and offers longitudinal follow-
up of patients while working for the same employer.19 The study was
determined to be exempt from full institutional review board review
by the University of North Carolina at Chapel Hill. The study protocol
was registered with the European Network of Centres for Pharmacoe-
pidemiology and Pharmacovigilance (ENCePP) on October 23, 2017
(EU PAS Register Number 21368, http://www.encepp.eu/encepp/
viewResource.htm?id=25456).
2.2 | Eligible population
The base population consisted of all MarketScan beneficiaries, aged
18 to 64 years, with at least one prescription dispensing claim for an
SGLT2 inhibitor, a DPP-4 inhibitor or an SU between March 1, 2013
and September 30, 2015. To ensure new use of either comparator
drug, we required patients to have ≥12 months of continuous Market-
Scan enrolment prior to the first eligible prescription dispensing claim,
during which no prescription for any of the study drug classes could
be observed (washout period).
2.3 | Exposure definition
Exposure to an SGLT2 inhibitor, a DPP-4 inhibitor or an SU
drug (Table S1) was defined by at least two same-class drug prescrip-
tion dispensing claims observed within a predefined window.
This “prescription window” was calculated as the first prescription's
recorded days' supply, plus a 30-day grace period. By requiring a sec-
ond prescription and using that prescription date as the index date,
we restricted the analysis to a cohort who we were reasonably confi-
dent were taking the cohort drug. Patients were excluded if they:
(a) received a prescription for either study drug prior to index date;
(b) switched to the comparator drug between the first and second pre-
scriptions; (c) received both study drugs on the index date; or
(d) received an empagliflozin-linagliptin combination drug on the index
date (Figure S1).
2.4 | Outcome definitions
The primary outcome of LEA was defined using a combination of
International Classification of Diseases, Ninth Revision, Clinical Modi-
fication and Common Procedural Terminology procedure codes.
Patients who experienced LEA between the first and second prescrip-
tions were included in the analysis, with those events captured in the
baseline amputation history. Secondary outcomes included other
diabetes-related conditions and procedures (tissue and bone debride-
ment, peripheral vascular disease, and diabetic foot ulcer) commonly
considered to be direct precursors or alternatives to LEA. Codes for all
outcome definitions were informed through prior literature20–30 and
clinical guidance (Table S2). For secondary analyses, we excluded
patients with baseline history of any outcome.
2.5 | Follow-up
The primary analysis was performed in an “as-treated” fashion
(Figure S2). Follow-up began at the index date (date of second pre-
scription) and ended when an individual experienced either an out-
come of interest or a censoring event (treatment discontinuation,
switch or augmentation; disenrolment; or September 30, 2015),
whichever came first. Secondary outcome analyses additionally cen-
sored patients if LEA was observed prior to occurrence of a secondary
outcome.
2.6 | Confounding control
We used propensity scores to control for measured confounding. We
incorporated covariate groupings for patient demographics, diabetes-
related comorbidities, general health comorbidities, medication use
history (including prior use of other GLDs), and measures of health-
care system use in the propensity-score model, measured in the year
prior to cohort entry (Table 1). We also applied the adjusted Diabetes
Complication Severity Index (aDCSI)31,32 as a proxy to control for dia-
betes disease severity.
2.7 | Statistical analysis
We estimated propensity scores using multivariable logistic regression
to model each patient's predicted probability of receiving an SGLT2
inhibitor, conditional on his or her baseline covariates. We then
weighted comparator cohorts by the propensity-score odds
(PS/[1-PS]) to standardize the distribution of measured covariates to
the SGLT2 inhibitor cohorts, and estimated the average treatment
TABLE 1 Baseline characteristics of the eligible initiators of sodium-glucose co-transporter-2 inhibitors compared with initiators of dipeptidyl
peptidase-4 inhibitors and sulphonylureas before and after implementation of standardized mortality ratio weightinga (365-day washout periodb)




(n = 49 324)
DPP-4 inhibitor
initiators




(n = 50 189)
SGLT2 inhibitor
initiators
(n = 46 878)
SU initiators
(n = 149 623)
Weighted SU
initiators
(n = 48 954)
Canagliflozin 34 700 (70.3) — — 32 452 (69.2) — —
Dapagliflozin 11 041 (22.4) — — 10 815 (23.1) — —
Empagliflozin 3583 (7.3) — — 3611 (7.7) — —
Mean (SD) age, years 52.5 (8.2) 52.8 (8.2) 52.3 (8.2) 52.3 (8.2) 51.0 (9.7) 52.3 (8.1)
Men, n (%) 26 039 (52.8) 65 941 (56.6) 25 499 (50.8) 24 468 (52.2) 78 710 (52.6) 25 019 (51.1)
Diabetes comorbiditiesb
Adjusted DCSI, mean (std. dev.) 0.7 (1.1) 0.6 (1.1) 0.7 (1.2) 0.7 (1.1) 0.6 (1.1) 0.7 (1.1)
Nephropathy, n (%) 2274 (4.6) 4480 (3.8) 2360 (4.7) 1928 (4.1) 4714 (3.2) 2089 (4.3)
Neuropathy, n (%) 5644 (11.4) 7848 (6.7) 6006 (12.0) 4941 (10.5) 8065 (5.4) 5445 (11.1)
Retinopathy, n (%) 4910 (10.0) 7593 (6.5) 4986 (9.9) 4351 (9.3) 7153 (4.8) 4816 (9.8)
Peripheral vascular
disease, n (%)
1396 (2.8) 3254 (2.8) 1459 (2.9) 1320 (2.8) 3364 (2.2) 1401 (2.9)
Prior LEA, n (%) 76 (0.2) 204 (0.2) 82 (0.2) 60 (0.1) 234 (0.2) 59 (0.1)
Debridement, n (%) 1107 (2.2) 2190 (1.9) 1180 (2.4) 993 (2.1) 2393 (1.6) 1091 (2.2)
Diabetic ulcer, n (%) 1031 (2.1) 2007 (1.7) 1105 (2.2) 950 (2.0) 2370 (1.6) 965 (2.0)
General health
comorbiditiesb, n (%)
Hypertension 35 035 (71.0) 76 079 (65.3) 35 864 (71.5) 32 882 (70.1) 90 326 (60.4) 34 576 (70.6)
Dyslipidaemia 36 678 (74.4) 76 080 (65.3) 37 260 (74.2) 34 736 (74.1) 83 601 (55.9) 36 655 (74.9)
Ischaemic heart disease 5019 (10.2) 11 658 (10.0) 5032 (10.0) 4606 (9.8) 13 082 (8.7) 4884 (10.0)
Cerebrovascular disease 1754 (3.6) 4494 (3.9) 1765 (3.5) 1645 (3.5) 5402 (3.6) 1739 (3.6)
Congestive heart failure 1075 (2.2) 3231 (2.8) 1094 (2.2) 940 (2.0) 3980 (2.7) 963 (2.0)
COPD 1292 (2.6) 3405 (2.9) 1382 (2.8) 1186 (2.5) 4307 (2.9) 1281 (2.6)
Depression 4829 (9.8) 9414 (8.1) 5173 (10.3) 4746 (10.1) 12 097 (8.1) 5139 (10.5)
History of cancer 2398 (4.9) 6054 (5.2) 2456 (4.9) 2315 (4.9) 7486 (5.0) 2392 (4.9)
Chronic kidney disease 4245 (8.6) 11 037 (9.5) 4494 (9.0) 3730 (8.0) 13 049 (8.7) 3975 (8.1)
Alcohol abuse 323 (0.7) 884 (0.8) 325 (0.6) 305 (0.7) 1461 (1.0) 294 (0.6)
Smoking 2462 (5.0) 6077 (5.2) 2551 (5.1) 2266 (4.8) 8625 (5.8) 2326 (4.8)
Prior medication useb, n (%)
ACE inhibitors 22 535 (45.7) 52 698 (45.3) 22 957 (45.7) 20 266 (43.2) 62 629 (41.9) 20 984 (42.9)
ARBs 13 898 (28.2) 28 923 (24.8) 14 255 (28.4) 13 581 (29.0) 29 055 (19.4) 14 711 (30.1)
Aspirin 2779 (5.6) 4594 (3.9) 3027 (6.0) 2655 (5.7) 5029 (3.4) 2883 (5.9)
β blockers 13 763 (27.9) 30 812 (26.5) 14 054 (28.0) 12 277 (26.2) 42 967 (28.7) 12 594 (25.7)
Calcium channel blockers 9680 (19.6) 23 313 (20.0) 9911 (19.7) 8872 (18.9) 28 005 (18.7) 9260 (18.9)
Statins 31 312 (63.5) 69 582 (59.8) 31 499 (62.8) 29 479 (62.9) 75 044 (50.2) 30 989 (63.3)
Loop diuretics 3615 (7.3) 7651 (6.6) 3891 (7.8) 3181 (6.8) 8910 (6.0) 3515 (7.2)
Non-loop diuretics 16 887 (34.2) 37 665 (32.3) 17 493 (34.9) 15 707 (33.5) 44 452 (29.7) 16 615 (33.9)
Digoxin 277 (0.6) 888 (0.8) 261 (0.5) 267 (0.6) 1003 (0.7) 265 (0.5)
Cilostazol 93 (0.2) 185 (0.2) 91 (0.2) 80 (0.2) 212 (0.1) 90 (0.2)
Gabapentin 4573 (9.3) 7965 (6.8) 4866 (9.7) 4137 (8.8) 9382 (6.3) 4509 (9.2)
Pregabalin 1390 (2.8) 2177 (1.9) 1487 (3.0) 1310 (2.8) 2153 (1.4) 1579 (3.2)
Duloxetine 2117 (4.3) 3710 (3.2) 2357 (4.7) 2097 (4.5) 3643 (2.4) 2415 (4.9)
Metformin 38 231 (77.5) 98 790 (84.8) 38 552 (76.8) 36 429 (77.7) 108 068 (72.2) 38 529 (78.7)
GLP-1 receptor agonists 13 950 (28.3) 5941 (5.1) 15 168 (30.2) 10 492 (22.4) 7372 (4.9) 12 640 (25.8)
DPP-4 inhibitors — — — 14 769 (31.5) 28 227 (18.9) 17 187 (35.1)
SUs 17 381 (35.2) 42 590 (36.6) 17 992 (35.8) — — —
Thiazolidinediones 4787 (9.7) 14 850 (12.8) 4903 (9.8) 4278 (9.1) 9930 (6.6) 4788 (9.8)
Insulin 16 162 (32.8) 14 687 (12.6) 17 150 (34.2) 14 685 (31.3) 13 259 (8.9) 16 488 (33.7)
effect in those treated.33 The aim of this approach was to address
the question, “Would LEA incidence have changed had all SGLT2
inhibitor initiators instead initiated a comparator drug?”. Covariate
balance was assessed using the standardized mean difference.34
For all outcomes, we estimated crude incidence rates (IRs) using
Poisson regression, and crude and adjusted HR (aHR) and 95% CIs
using weighted Cox proportional hazards models. We used weighted
Kaplan–Meier methods to estimate the cumulative incidence of LEA,
TABLE 1 (Continued)




(n = 49 324)
DPP-4 inhibitor
initiators




(n = 50 189)
SGLT2 inhibitor
initiators
(n = 46 878)
SU initiators
(n = 149 623)
Weighted SU
initiators
(n = 48 954)
Measures of healthcare utilization
in year prior to index dateb, n (%)
Number of HbA1c tests in past year
0 4101 (8.3) 13 706 (11.8) 3959 (7.9) 3925 (8.4) 31 605 (21.1) 4174 (8.5)
1 9564 (19.4) 31 526 (27.1) 9975 (19.9) 9295 (19.8) 44 163 (29.5) 9014 (18.4)
2 13 699 (27.8) 33 432 (28.7) 14 085 (28.1) 13 232 (28.2) 37 179 (24.8) 13 296 (27.2)
3 21 960 (44.5) 37 775 (32.4) 22 170 (44.2) 20 426 (43.6) 36 676 (24.5) 22 469 (45.9)
Number of LDL tests in past year
0 7040 (14.3) 20 606 (17.7) 7345 (14.6) 6670 (14.2) 42 324 (28.3) 7171 (14.6)
1 16 478 (33.4) 42 377 (36.4) 16 522 (32.9) 15 532 (33.1) 54 070 (36.1) 15 061 (30.8)
2 14 185 (28.8) 31 861 (27.4) 14 720 (29.3) 13 438 (28.7) 33 046 (22.1) 14 191 (29.0)
3 11 621 (23.6) 21 595 (18.5) 11 602 (23.1) 11 238 (24.0) 20 183 (13.5) 12 531 (25.6)
Flu shot received in past year 16 077 (32.6) 34 584 (29.7) 16 374 (32.6) 15 218 (32.5) 42 827 (28.6) 15 911 (32.5)
Number of hospitalizations
0 45 735 (92.7) 105 388 (90.5) 46 412 (92.5) 43 543 (92.9) 133 177 (89.0) 45 552 (93.1)
1 2976 (6.0) 8678 (7.5) 3122 (6.2) 2757 (5.9) 12 963 (8.7) 2839 (5.8)
2 450 (0.9) 1615 (1.4) 475 (0.9) 426 (0.9) 2392 (1.6) 399 (0.8)
≥3 163 (0.3) 758 (0.7) 180 (0.4) 152 (0.3) 1091 (0.7) 163 (0.3)
Number of days in hospital
0 45 735 (92.7) 105 388 (90.5) 46 412 (92.5) 43 543 (92.9) 133 177 (89.0) 45 552 (93.1)
1-2 1471 (3.0) 3988 (3.4) 1542 (3.1) 1346 (2.9) 5822 (3.9) 1363 (2.8)
3-5 1268 (2.6) 3730 (3.2) 1334 (2.7) 1215 (2.6) 5657 (3.8) 1252 (2.6)
5-10 501 (1.0) 1739 (1.5) 519 (1.0) 461 (1.0) 2641 (1.8) 478 (1.0)
>10 349 (0.7) 1594 (1.4) 382 (0.8) 313 (0.7) 2326 (1.6) 309 (0.6)
Number of emergency
department visits
0 39 544 (80.2) 92 730 (79.6) 39 938 (79.6) 37 775 (80.6) 115 887 (77.5) 39 563 (80.8)
1 6751 (13.7) 16 338 (14.0) 6949 (13.8) 6280 (13.4) 22 788 (15.2) 6436 (13.1)
≥2 3029 (6.1) 7371 (6.3) 3302 (6.6) 2823 (6.0) 10 948 (7.3) 2955 (6.0)
Number of physician encounters
0 162 (0.3) 662 (0.6) 155 (0.3) 162 (0.3) 1365 (0.9) 162 (0.3)
1-3 3152 (6.4) 12 227 (10.5) 3131 (6.2) 3019 (6.4) 20 497 (13.7) 2952 (6.0)
4-6 7665 (15.5) 22 349 (19.2) 7695 (15.3) 7333 (15.6) 28 773 (19.2) 7365 (15.0)
≥7 38 345 (77.7) 81 201 (69.7) 39 208 (78.1) 36 364 (77.6) 98 988 (66.2) 38 475 (78.6)
Number of podiatrist visits
0 44 392 (90.0) 107 032 (91.9) 45 105 (89.9) 42 275 (90.2) 139 833 (93.5) 44 034 (89.9)
1 2309 (4.7) 4547 (3.9) 2401 (4.8) 2144 (4.6) 4904 (3.3) 2306 (4.7)
2 1078 (2.2) 2102 (1.8) 1145 (2.3) 1063 (2.3) 2210 (1.5) 1108 (2.3)
≥3 1545 (3.1) 2758 (2.4) 1538 (3.1) 1396 (3.0) 2676 (1.8) 1506 (3.1)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; COPD, chronic obstructive pulmonary disease; DCSI, diabetes
complication severity index; DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin; LEA,
lower-extremity amputation; SGLT2, sodium-glucose co-transporter-2; SU, sulphonylurea.
a Weighted by standardizing the comparator drug initiators to the population of SGLT2 inhibitor initiators, using the propensity-score odds (PS/(1-PS)), to
estimate the treatment effect in those treated.
b All baseline characteristics measured in the 1 year (365 days) prior to date of cohort drug initiation.
as well as risk differences and 95% CIs in the 1 to 30, 31 to 90, 91 to
180, and ≥180 days after drug initiation in each study cohort. All ana-
lyses were performed using SAS version 9.4 (SAS Institute Inc., Cary,
North Carolina).
2.8 | Sensitivity and subgroup analyses
We conducted multiple sensitivity analyses. First, we re-analysed the
data using an intention-to-treat (ITT) follow-up approach for up to
1 year, whereby patients were censored only for disenrolment or at
the administrative study end date. Second, similarly to previous
studies,11–14 we performed an analysis requiring only a single pre-
scription claim to be considered exposed to a study drug. Third, to
replicate comparator choices in previous studies, we conducted an
analysis using any non-metformin, non-SGLT2 inhibitor GLD (SUs,
thiazolidinediones, DPP-4 inhibitors, glucagon-like peptide-1 receptor
agonists, and insulins) as the comparator group, excluding all patients
with baseline use of these agents. Fourth, because LEA risk was spe-
cifically noted in the CANVAS programme, we repeated the analysis,
restricting it to canagliflozin users.
To assess the impact of various design specifications, we repeated
the analyses using 15-, 60-, and 90-day grace periods; 30-, 60-, 90-,
and 180-day induction periods; 30-, 60-, 90-, and 180-day latency
periods; and a 6-month washout period. We specified a range of
induction and latency periods a priori to determine possible durations
of time required for treatment initiation to contribute to LEA occur-
rence; both periods were extended to 6 months to reflect CANVAS
results that reported emerging amputation risk by 6 months of follow-
up. We additionally repeated the analysis with 1%, 2.5% and 5%
asymmetric trimming of the propensity score distribution.35
The CANVAS programme reported a particularly elevated risk of
LEA among patients with an LEA history, which could have important
implications for clinical decision-making. To validate this result in our
cohort, we estimated LEA risk within subgroups with and without
prior amputation in the year prior to cohort entry. Because baseline
metformin use predicts diabetes-related cardiovascular endpoints
among users of second-line GLDs,36 we estimated and compared
stratum-specific HR estimates among patients with and without base-
line metformin use in the year prior to cohort entry. Finally, to investi-
gate the impact of other baseline GLD use and to compare results
with previous literature, we performed subgroup analyses by baseline
SU use, baseline insulin use, baseline cardiovascular disease (CVD) sta-
tus, and baseline chronic kidney disease (CKD) status.
3 | RESULTS
3.1 | Eligible cohort
We identified a total of 328 150 eligible users of at least one study
drug in the MarketScan database between March 1, 2013 and
September 30, 2015. Among study patients, we identified a total of
165 763 eligible new users in the SGLT2 inhibitor (n = 49 324) ver-
sus DPP-4 inhibitor (n = 116 439) comparison and 196 501 eligible
new users for the SGLT2 inhibitor (n = 46 878) versus SU
(n = 149 623) comparison. Canagliflozin, dapagliflozin and empagliflozin
accounted for 69% to 70%, 22% to 23%, and 7% to 8% of SGLT2
inhibitor use, respectively (Table 1). The median (interquartile range
[IQR]) follow-up (Table 2) in the as-treated analyses was slightly lon-
ger among comparator drug initiators, and ranged from 0.42
(0.21-0.76) years among SGLT2 inhibitor initiators to 0.47
(0.25-0.94) years among DPP-4 inhibitor initiators. The median
(IQR) follow-up was longer in the ITT analysis, again among compar-
ator drug initiators, ranging from 0.64 (0.31-1.05) years in SGLT2
inhibitor initiators to 1.06 (0.46-2.01) years among DPP-4 inhibitor
initiators and 1.03 (0.46-1.86) years among SU initiators. Follow-up
was capped at 1 year after index date to minimize this observed
difference in person-time available.
Age and gender distributions were similar across cohorts
(Table 1). Prior to standardized mortality ratio (SMR) weighting, we
observed imbalances in several baseline comorbidities, including
diabetic nephropathy, neuropathy, hypertension, dyslipidaemia,
ischaemic heart disease, and baseline use of angiotensin-receptor
blockers, statins and metformin; baseline imbalances were gener-
ally more pronounced in the SGLT2 inhibitor versus SU compari-
son. All measured covariates were balanced after SMR weighting
(Figure S4).
3.2 | Primary and secondary outcomes
In the as-treated analysis (Table 2), we identified 185 LEA events in
the SGLT2 inhibitor (n = 63) versus DPP-4 inhibitor (n = 122) compar-
ison, and 234 LEA events in the SGLT2 inhibitor (n = 50) versus SU
(n = 184) comparison. The majority of amputations were of the toe
and metatarsal (83%), foot and ankle (7%), and lower leg (9%). Abso-
lute LEA risks were low in all cohorts (Figure 1 and Table S3). Crude
IRs were higher among SGLT2 inhibitor initiators (2.4 per 1000
person-years, 95% CI 1.8-3.0) than among DPP-4 inhibitor initiators
(1.5 per 1000 person-years, 95% CI 1.2-1.8), but were similar between
SGLT2 inhibitor (2.0 per 1000 person-years, 95% CI 1.5-2.6) and SU
(1.8 per 1000 person-years, 95% CI 1.6-2.1) initiators.
Hazard ratio estimates were similar in the crude and adjusted ana-
lyses. After controlling for baseline confounding via SMR weighting,
we observed an increased hazard of LEA among SGLT2 inhibitor initi-
ators versus DPP-4 inhibitor initiators (aHR 1.69, 95% CI 1.20-2.38);
however, no association was observed when comparing SGLT2 inhibi-
tor with SU initiators (aHR 1.02, 95% CI 0.67-1.55). To further aid
clinical decision-making on second-line therapies, we performed a
post hoc analysis comparing DPP-4 inhibitor initiators with SU initia-
tors, and observed a reduced hazard of LEA among DPP-4 inhibitor
initiators (aHR 0.67, 95% CI 0.49-0.91), which is consistent with the
primary analysis findings. Finally, no increased hazard of LEA was
observed when comparing initiators of SGLT2 inhibitors with initiators
of all non-metformin, non-SGLT2 inhibitor GLDs (aHR 1.02, 95% CI
0.54-1.93), although we observed notable differences between crude
and adjusted estimates in this comparison. For secondary outcomes,
we observed modest to no increases in LEA hazard (Table S4), with
HR estimates ranging from 0.96 to 1.22, and all 95% CIs containing
the null.
3.3 | Sensitivity and subgroup analyses
Results were consistent across a number of sensitivity analyses
(Figure 2, Tables S5 and S6). We observed a downward trend in
HR estimates for ITT analysis, when requiring only one prescrip-
tion to define exposure, when using longer grace periods, latency,
and induction periods, and when greater trimming was performed.
In the SU comparison, HR estimates increased when using 60- and
90-day induction periods, although estimates remained nonsignifi-
cant. Requiring a shorter (6-month) washout period did not sub-
stantially change HR estimates. Finally, restriction to just
canagliflozin initiators yielded higher HR estimates in both the
DPP-4 inhibitor and SU comparisons, but lower HR estimates ver-
sus non-metformin, non-SGLT2 inhibitor initiators (aHR 0.85, 95%
CI 0.38-1.91).
Subgroup analysis results suggested possible differences in LEA
risk by baseline metformin and insulin use, and history of amputation,
CVD and CKD (Figure 2). In both DPP-4 inhibitor and SU compari-
sons, we observed higher HR estimates among patients with history
of amputation, with baseline insulin use, and with history of CKD.
Baseline metformin use and history of CVD were associated with
higher HR estimates in the SU comparison, but lower HR estimates in
the DPP-4 inhibitor comparison. We did not observe evidence of
modification by baseline SU use.
4 | DISCUSSION
In this large, ACNU cohort study among commercially insured US
patients, we observed a statistically significant elevation in LEA risk
among SGLT2 inhibitor initiators versus DPP-4 inhibitor initiators
(aHR 1.69, 95% CI 1.20-2.38), but not versus SU initiators (aHR 1.02,
95% 0.67-1.55). Primary analysis results remained consistent across a
number of sensitivity analyses. We observed modest to no increases
in risk for the secondary outcomes of debridement, peripheral vascu-
lar disease, and diabetic foot ulcer. Finally, risk appeared elevated in
patients with history of amputation and CKD, and baseline insulin use,
although these estimates were not statistically significant.
Results from this analysis join a growing body of evidence sur-
rounding the risk of LEA associated with use of SGLT2 inhibitors
(Table 3). Recent ITT analyses conducted in the MarketScan CCAE
population by Yuan et al11 (aHR 0.98, 95% CI 0.68-1.41) and Ryan
et al12 (aHR 1.01, 95% CI 0.80-1.28) reported null associations of
below-knee amputation risk among new users of canagliflozin versus
TABLE 2 Crude and adjusted hazard ratio estimates for lower-extremity amputation and with initiation of sodium-glucose co-transporter-2























AT analysis SGLT2 inhibitor 49 324 0.42 (0.21-0.76) 26 751 63 2.4 (1.8-3.0) 1.54 (1.13-2.10) 1.69 (1.20-2.38)
DPP-4 inhibitor 116 439 0.47 (0.25-0.94) 82 947 122 1.5 (1.2-1.8)
ITT analysis SGLT2 inhibitor 49 324 0.64 (0.31-1.00) 30 362 70 2.3 (1.8-2.9) 1.45 (1.08-1.93) 1.43 (1.01-2.03)
DPP-4 inhibitor 116 439 1.00 (0.46-1.00) 86 187 136 1.6 (1.3-1.9)
SGLT2 inhibitors
vs. SUs
AT analysis SGLT2 inhibitor 46 878 0.42 (0.21-0.76) 25 427 50 2.0 (1.5-2.6) 1.06 (0.77-1.45) 1.02 (0.67-1.55)
SU 149 623 0.43 (0.22-0.91) 102 058 184 1.8 (1.6-2.1)
ITT analysis SGLT2 inhibitor 46 878 0.64 (0.31-1.00) 28 900 56 1.9 (1.5-2.5) 1.01 (0.75-1.36) 1.02 (0.69-1.50)




AT analysis SGLT2 inhibitor 15 687 0.35 (0.17-0.64) 7275 10 1.4 (0.7-2.6) 0.66 (0.35-1.24) 1.02 (0.54-1.93)
Non-SGLT2
inhibitor
224 363 0.41 (0.20-0.86) 148 171 282 1.9 (1.7-2.1)
ITT analysis SGLT2 inhibitor 15 687 0.57 (0.28-0.97) 9152 13 1.4 (0.8-2.4) 0.66 (0.38-1.16) 1.06 (0.60-1.86)
Non-SGLT2
inhibitor
224 363 0.99 (0.44-1.00) 162 958 340 2.1 (1.9-2.3)
Abbreviations: AT, as-treated; CI, confidence interval; DPP-4, dipeptidyl peptidase-4; HR, hazard ratio; IQR, interquartile range; ITT, intention-to-treat; PS,
propensity score; SGLT2 inhibitor, sodium-glucose cotransporter-2; SU, sulphonylurea.
a Follow-up in ITT analyses was capped at 1 year following the index date.
b We observed 51, 59 and 102 lower-extremity amputation events between the first and second prescription fills in the DPP-4 inhibitor, SU and
non-SGLT2 inhibitor comparisons, respectively. These patients were not excluded from the primary analysis, but were considered as prior amputations
for the assessment of subgroup effects for patients with and without prior amputation history. These amputations were re-introduced as analysis end-
points for the sensitivity analysis where we include patients with at least 1 prescription fill.
new users of all non-SGLT2 inhibitor GLDs.11,12 Using as-treated anal-
ysis, Dawwas et al16 obtained a similar result versus both DPP-4
inhibitor (aHR 0.88, 95% CI 0.65-1.15) and SU users (aHR 0.74, 95%
CI 0.57-0.96), and Ryan et al12 reported a protective effect of SGLT2
inhibitors versus all non-SGLT2 inhibitor GLDs (aHR 0.56, 95% CI
0.32-0.92).
By contrast, also using MarketScan CCAE, Chang et al13 (aHR
1.50, 95% CI 0.85-2.67) and Adimadhyam et al14 (aHR 1.38, 95% CI
0.83-2.31) have suggested the possibility of increased LEA risk associ-
ated with new use of SGLT2 inhibitor agents, versus new use of DPP-
4 inhibitors. However, low event counts and more rigid cohort exclu-
sions in both studies contributed to limited precision and CIs that con-
tained the null. Finally, studies by Udell et al15 (aHR 2.01, 95% CI
0.89-4.53) and Ueda et al37 (aHR 2.32, 95% CI 1.37-3.91) obtained
similar results to those of the CANVAS programme in different popu-
lations, although older mean age of patients in all three studies could
be an underlying contributor.
In the present study, which was planned and prespecified in
2017 prior to publication of other pharmaco-epidemiological ana-
lyses, we observed a similarly elevated risk of LEA among SGLT2
inhibitor initiators versus DPP-4 inhibitor comparators, and a similar
null result versus initiators of all non-metformin, non-SGLT2 inhibitor
GLDs (aHR 1.02, 95% CI 0.54-1.93). However, results from the SU
and non-SGLT2 inhibitor comparisons were both substantively differ-
ent from the results obtained by Chang et al,13 who made their com-
parisons against a suite of older GLDs including metformin, SUs and
thiazolidinediones (aHR 2.12, 95% CI 1.19-3.77). We attribute these
differences to our simultaneous inclusion of insulin (typically a
marker of more severe diabetes and higher amputation risk) and
exclusion of metformin (often prescribed to patients with less severe
diabetes and lower amputation risk) in the non-SGLT2 inhibitor com-
parator group, which mirrors a commonly used comparator in previ-
ous studies.11,12,15
Because the potential mechanisms behind SGLT2 inhibitor and
amputation risk remain undetermined – current hypotheses relate to
volume depletion and reduced tissue perfusion11 – we assert that the
heterogeneity of findings results primarily from differences in study
design decisions. We show that inference regarding comparative LEA
risk changes meaningfully when different active comparators (DPP-4
inhibitor vs. SU vs. non-metformin, non-SGLT2 inhibitor GLDs) are
employed. We also highlight the important differences between
patients prescribed these drugs in practice, which is underscored by
the crude baseline differences observed between SGLT2 inhibitor and
SU initiators (Table 1), and between SGLT2 inhibitor and non-metfor-
min, non-SGLT2 inhibitor initiators (Table S7). Sulphonylureas, for
example, while often categorized as a second-line GLD in current dia-
betes pharmacotherapy guidelines, may not be an ideal analytical
alternative to SGLT2 inhibitors because they are less costly and may
be more frequently prescribed to patients with lower socio-economic
status and healthcare system access.38–40 Furthermore, often in
restrictive, protocol-driven health systems, approaches are adopted
that spare the use of more recent diabetes therapies, such as SGLT2
inhibitors, until after SU treatment has failed. This has previously been
FIGURE 1 Standardized mortality ratio (SMR)-weighted* Kaplan–
Meier curves for lower-extremity amputation after drug initiation,
with 365-day washout period. *Weighted by standardizing the
comparator drug initiators to the population of sodium-glucose co-
transporter-2 (SGLT2) inhibitor initiators, using the propensity score
odds (PS/[1-PS]), to estimate the treatment effect in the treated
(ATT). DPP-4, dipeptidyl peptidase-4; SU, sulfonylureas
demonstrated in the Medicare population, where SUs are often
used as a first-line therapy as an alternative to metformin.41,42
Crude imbalances between SGLT2 inhibitor and non-metformin,
non-SGLT2 inhibitor initiators were even more severe (Table S7). In
particular, baseline CKD imbalances suggest the possibility of channel-
ing by contraindication. Although presence of CKD was balanced after
SMR weighting, this crude imbalance suggests that “catch-all” compar-
ator groups that combine different-line diabetes therapies are not
recommended for comparative effectiveness and safety studies.
Proper selection of appropriate clinical alternatives can enhance the
ability of comparative safety studies to inform clinical decision-making
around prescribing of similar-line medications to treat T2DM.
Other study design decisions have also contributed to the hetero-
geneous results of studies conducted in the MarketScan CCAE
(Table 3). First, the present study, which is the first on this topic to
define diabetes drug exposure using at least two prescriptions, shows
that analyses defining exposure with only one prescription claim
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FIGURE 2 Crude and adjusted hazard ratio estimates for lower-extremity amputation with initiation of sodium-glucose co-transporter-2 (SGLT2)
inhibitors vs. initiation of other second-line glucose-lowering drugs, sensitivity and subgroup analyses. AT, as-treated; BL, baseline; DPP-4,
dipeptidyl peptidase-4; Hx, history; IQR, interquartile range; ITT, intention-to-treat; SMR, standardized mortality ratio; SUs, sulphonylureas.
aWeighted by standardizing the comparator drug initiators to the population of SGLT2i initiators, using the propensity score odds (PS/(1-PS)), to
estimate the treatment effect in the treated (AT). bPrimary analyses performed with both induction and latency periods = 0. cHolding induction
period constant (=0). dHolding latency period constant (=0). eSubgroup analyses adjusted for age, sex, baseline neuropathy, baseline peripheral





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































canagliflozin-only analyses yielded higher HR estimates versus DPP-4
inhibitor and SU initiators, but lower HR estimates versus non-metfor-
min, non-SGLT2 inhibitor initiators. This last result is more consistent
with the canagliflozin-specific HR estimates observed by Yuan et al11
and Ryan et al.12 Third, analyses using ITT follow-up typically yielded
HR estimates closer to the null than those using as-treated
approaches, which may have contributed to the observed differences
between Yuan et al11 and Ryan et al,12 versus Chang et al,13 Adimad-
hyam et al,14 and the present study. Fourth, our subgroup analyses
showed that excluding patients with prior amputation and prior CKD
reduced HR estimates, whereas excluding patients with baseline insu-
lin use increased HR estimates.
Finally, differences in propensity-score methods and confounder
sets can affect the extent to which confounding by indication and dia-
betes severity is controlled. Kaiser et al43 have previously shown that
potential for residual confounding can vary substantially depending on
the outcome under study. Given that studies typically define a single
set of confounders, one implication is that confounding control may
be more complete in studies that apply these confounders to assess
amputation risk alone,11,13,14 versus those that use the same con-
founders to assess both beneficial and adverse outcomes5,15,16 or to
assess multiple adverse outcomes with different mechanisms.37 In the
present study, we aimed to minimize residual confounding by includ-
ing confounders specific to amputation risk, and prespecified second-
ary outcomes that we believe share a similar mechanism to
amputation risk.
Ultimately, authors should justify study design choices to reflect
the specific clinical question(s) under study, and provide transparency
when communicating data for clinical and regulatory decision-making.
The present study aimed to address the question, “Would LEA inci-
dence have changed had all initiators of SGLT2 inhibitor instead initi-
ated a similar, second-line diabetes drug?”. To reflect this aim, we
prespecified our primary analysis to: (a) focus on new users;
(b) compare with only similar second-line therapies (DPP-4 inhibitors
and SUs, rather than all non-SGLT2 inhibitor GLDs); (c) require at least
two prescription dispensing claims as an indicator of adherence;
(d) focus on below-knee amputation for consistency with CANVAS
findings; (e) employ as-treated follow-up; and (f) perform confounding
control via SMR weighting to estimate the average treatment effect in
those treated. We then performed a number of sensitivity and sub-
group analyses to test the robustness of our primary analysis to differ-
ent study design choices and specifications, and to quantify the
impacts of excluding and stratifying by prior comorbidity and GLD use
histories. As analytical approaches continue to evolve around ques-
tions of LEA risk with SGLT2 inhibitor use, our understanding of
SGLT2 inhibitor effectiveness and safety will continue to deepen.
The present study had several strengths. First, the ACNU study
design helps to address issues related to confounding by indication
by comparing patients treated with similar second-line T2DM ther-
apies, and provides additional control for other unmeasured con-
founders and for various time-related biases.17 Second, propensity-
score weighting adequately controlled for remaining measured
baseline confounding, as shown in Table 1. We controlled for base-
line use of other oral GLDs, including metformin and insulin, which
were not controlled for in several previous studies.11,13 Third, by
restricting to patients with at least two prescriptions in close prox-
imity, we gain confidence that patients are actually taking the study
drugs. The commonly used approach of defining exposure through
a single prescription claim alone can include patients who are not
actually on therapy, as prescription dispensing claims do not neces-
sarily reflect whether patients actually take the study drugs after
filling the prescription. In our analysis, >30% of patients with one
study drug prescription did not fill a second prescription within the
allotted prescription window (Figure S1, Tables S5 and S6). These
patients, who contributed 26% of follow-up time in time-to-event
analyses, may represent misclassified “exposed” time. Our results
indicate that requiring the second prescription, which has not previ-
ously been implemented in similar studies, reduces bias towards the
null.44
Finally, we were able to leverage the size of the MarketScan
CCAE database to assess subgroup differences by a number of
baseline characteristics. Multiple studies have assessed possible
differences in amputation risk by CVD status, but no previous
observational studies have, to our knowledge, assessed differences
in HR by prior amputation history and baseline metformin use.
Although differences in subgroup analyses were modest and preci-
sion of estimates was limited because of low event counts, these
analyses can nevertheless offer important insight to aid physician
decision-making when weighing clinical alternatives among
patients with specific comorbidity and diabetes medication use
histories.
The present study also had the limitations characteristic of
observational studies using administrative data. First, although the
MarketScan CCAE database contains data for patients aged
≥65 years, data for these patients are inconsistently reported in
MarketScan owing to the priority of Medicare coverage among such
patients. To account for these potentially missing claims data, we
limited our analysis to employer-insured patients aged <65 years,
for whom we are confident data are relatively complete. Thus, our
findings may not be generalizable to older or unemployed popula-
tions, which may have different amputation risk. Second, although
we restricted the analyses to patients aged ≥18 years as a proxy for
patients with T2DM, patients with Type 1 diabetes mellitus (T1DM)
may also be present in the study cohort. However, the treatment
patterns assessed in this study are more indicative of T2DM, since
oral GLDs are uncommonly prescribed in T1DM.45 Third, the Mar-
ketScan CCAE database does not report patient vital status, which
precluded modelling of death as a competing risk. However, we did
not expect death to be a major competing risk given the short
(<1 year) follow-up in our cohort and relatively low mortality
expected among the younger, privately-insured population. Fourth,
because canagliflozin has dominated SGLT2 inhibitor use in the
United States thus far, we did not have sufficient power to study
dapagliflozin and empagliflozin individually, and were unable to
determine to what extent the class effect observed in this study
extends to dapagliflozin and empagliflozin.46 However, use of dapa-
gliflozin and empagliflozin continues to grow, and evidence should
emerge in the coming years. Finally, we acknowledge the possibility
of unmeasured confounding attributable to the observational
nature of this study and the lack of data on race/ethnicity and
socio-economic status. However, we were able to provide partial
control through claims-based definitions of dyslipidaemia, aDCSI,
smoking cessation, and chronic obstructive pulmonary disease as
proxies for patient body mass index, diabetes severity and duration,
and smoking status, respectively.
In conclusion, the present cohort study adds to, and contextual-
izes, existing evidence by demonstrating that initiation of SGLT2
inhibitors may be associated with an increased LEA risk versus initia-
tion of DPP-4 inhibitors, but not SUs. We provide evidence that risk
may be greater in patients with history of LEA, history of CKD, or
baseline insulin use. Study design decisions, particularly the choice of
active comparator drug, can meaningfully impact HR estimates and
downstream conclusions about the comparative safety of SGLT2
inhibitor and its clinical alternatives. As data continue to accrue
around SGLT2 inhibitor-prescribing in real-world patient populations,
analytical approaches must continue to evolve to address questions
appropriately that deepen our clinical understanding of benefits and
risks with SGLT2 inhibitor use.
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